Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. The company is headquartered in San Francisco, California and currently employs 61 full-time employees. The company is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. The company is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.
Follow-Up Questions
Who is the CEO of Nektar Therapeutics?
Mr. Howard Robin is the President of Nektar Therapeutics, joining the firm since 2007.
What is the price performance of NKTR stock?
The current price of NKTR is $56.02, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Nektar Therapeutics?
Nektar Therapeutics belongs to Pharmaceuticals industry and the sector is Health Care
What is Nektar Therapeutics market cap?
Nektar Therapeutics's current market cap is $1.0B
Is Nektar Therapeutics a buy, sell, or hold?
According to wall street analysts, 9 analysts have made analyst ratings for Nektar Therapeutics, including 5 strong buy, 6 buy, 2 hold, 1 sell, and 5 strong sell
